We are live on ! Find out more
LCP

Lamond Capital Partners Portfolio holdings

AUM $14.3M
1-Year Est. Return 30.74%
This Fund
S&P 500
This Quarter Est. Return
-21.94%
1 Year Est. Return
-30.74%
3 Year Est. Return
+54.28%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$134M
AUM Growth
+$35.1M
Cap. Flow
+$61.6M
Cap. Flow %
46.12%
Top 10 Hldgs %
100%
Holding
18
New
7
Increased
3
Reduced
–
Closed
8

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$13.4M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$13.3M
3
CY
Cypress Semiconductor
CY
+$11.5M
4
OCUL icon
Ocular Therapeutix
OCUL
+$10.5M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$7.91M

Top Sells

Rank Stock Value
1
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$14.1M
2
HPQ icon
HP
HPQ
+$10.1M
3
VMEM
VIOLIN MEMORY, INC.
VMEM
+$9.64M
4
HOS
Hornbeck Offshore Services, Inc.
HOS
+$7.24M
5
KITE
Kite Pharma, Inc.
KITE
+$6.64M

Sector Composition

Rank Sector Weight
1 Healthcare 51.12%
2 Technology 7.01%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMGN icon
1
CALL
Amgen
AMGN
$203B
$20.7M 15.53%
+150,000
New +$23.6M
ORCL icon
2
CALL
Oracle
ORCL
$331B
$18.1M 13.52%
+500,000
New +$19.2M
OCUL icon
3
Ocular Therapeutix
OCUL
$1.86B
$17.3M 12.98%
1,233,285
+521,752
+73% +$10.5M
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$15.6M 11.7%
100,000
+43,390
+77% +$7.91M
AMGN icon
5
Amgen
AMGN
$203B
$13.8M 10.35%
100,000
+3,370
+3% +$531K
ABBV icon
6
CALL
AbbVie
ABBV
$458B
$13.6M 10.18%
+250,000
New +$16.3M
GWPH
7
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$11M 8.21%
+120,000
New +$13.3M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$11.5B
$10.5M 7.88%
+100,000
New +$13.4M
CY
9
DELISTED
Cypress Semiconductor
CY
$9.37M 7.01%
+1,100,000
New +$11.5M
KITE
10
CALL
DELISTED
Kite Pharma, Inc.
KITE
$3.53M 2.64%
+63,400
New +$3.99M
HPQ icon
11
HP
HPQ
$23.5B
– –
-742,074
Closed -$10.1M
ALPN
12
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-56,250
Closed -$3.41M
BLCM
13
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-6,878
Closed -$1.46M
SIOX
14
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-86,620
Closed -$14.1M
HOS
15
DELISTED
Hornbeck Offshore Services, Inc.
HOS
– –
-352,720
Closed -$7.24M
KITE
16
DELISTED
Kite Pharma, Inc.
KITE
– –
-105,498
Closed -$6.64M
BLOX
17
DELISTED
Infoblox Inc
BLOX
– –
-230,872
Closed -$6.05M
VMEM
18
DELISTED
VIOLIN MEMORY, INC.
VMEM
– –
-983,645
Closed -$9.64M

Similar funds

HCM
Hirzel Capital Management Dallas, Texas $15.1M AUM 5.29% 1-Year Est. Return
PPF
PartnerRe Principal Finance Greenwich, Connecticut $15.5M AUM 13.01% 1-Year Est. Return
PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
TSU
TD Securities (USA) New York $11M AUM 2.35% 1-Year Est. Return
RCMC
Rubric Capital Management (Connecticut) Stamford, Connecticut $6.44M AUM 43.01% 1-Year Est. Return
SCA
Strategic Capital Alternatives Gig Harbor, United States $6.3M AUM
GFWEV
G.F.W. Energy VII Irving, Texas $1.49M AUM 89.53% 1-Year Est. Return
STA
System Two Advisors Summit, New Jersey $23K AUM 23.64% 1-Year Est. Return

Lamond Capital Partners's Q3 2015 Portfolio in Review

As of Q3 2015, Lamond Capital Partners held 18 positions worth $134M, up 36% from $98.5M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Lamond Capital Partners deployed $61.6M of net new capital in Q3 2015, opening 7 new positions and adding to 3 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 100,000 shares worth $10.5M.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 60% a quarter earlier, followed by Technology and Industrials.

On the sell side, the most notable exit was Sio Gene Therapies Inc. Common Stock, an estimated $14.1M sold.

  • Lamond Capital Partners's largest Q3 2015 buy was BioMarin Pharmaceuticals: 100,000 shares worth $10.5M.
  • Lamond Capital Partners added most to Ocular Therapeutix in Q3 2015, an estimated $10.5M increase.
  • Lamond Capital Partners fully exited Sio Gene Therapies Inc. Common Stock in Q3 2015, selling an estimated $14.1M.
  • Lamond Capital Partners's ten largest holdings make up 100% of its $134M portfolio in Q3 2015.
  • Lamond Capital Partners opened 7 new positions and closed 8 in Q3 2015.
  • Lamond Capital Partners's portfolio value rose 36% quarter-over-quarter to $134M.

Based on Lamond Capital Partners's 13F filing for Q3 2015, filed 9 Nov 2015.